| Biological Information | |
|---|---|
| Background Information: | The RET (rearranged during transfection) receptor tyrosine kinase is a classic example of phenotype heterogeneity. Gain-of-function mutations of RET are associated with human cancer and multiple endocrine neoplasia type 2 (MEN 2A, MEN 2B, etc.) Loss-of-function mutations of RET cause Hirschspung disease or colonic aganglionosis).
GenBank NM_000323 |
| Target Class: | Kinase |
| Accession Number: | NM_000323 |
| Target Name: | Ret |
| Target Aliases: | RET, CRET, CDHF12 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Ret (V804L), active
N-terminal GST-tagged recombinant, human Ret amino acids 658 – end containing the V804L mutation. The V804L mutation has been identified in patients with familial medullary thyroid carcinoma (FMTC) (Lombardo F. et al., (2002), JCEM, 87, 1674-1680; Lesueur F. et al, (2005), JCEM, 90, 3454-3457).
Datasheets
14-758x Datasheet
View Document